Jump Financial LLC Acquires New Position in Arcellx, Inc. (NASDAQ:ACLX)

Jump Financial LLC bought a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,359 shares of the company's stock, valued at approximately $334,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in shares of Arcellx in the 4th quarter valued at about $41,000. KBC Group NV lifted its holdings in Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock valued at $106,000 after acquiring an additional 377 shares during the period. Avanza Fonder AB acquired a new stake in shares of Arcellx during the 4th quarter worth approximately $184,000. Kazazian Asset Management LLC acquired a new position in shares of Arcellx in the 4th quarter valued at $204,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Arcellx during the fourth quarter worth $214,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Arcellx Trading Up 0.9 %

ACLX traded up $0.61 on Thursday, reaching $65.56. The stock had a trading volume of 68,921 shares, compared to its average volume of 552,664. The business's 50-day moving average price is $64.77 and its two-hundred day moving average price is $74.43. The company has a market cap of $3.61 billion, a P/E ratio of -92.33 and a beta of 0.33. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The business had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. As a group, analysts predict that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Christopher Heery sold 10,155 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the sale, the insider now owns 37,486 shares of the company's stock, valued at $2,391,231.94. The trade was a 21.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total transaction of $86,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,955 shares of company stock valued at $3,504,758. 6.24% of the stock is owned by corporate insiders.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).